P2.13-33 a Case Report of Exceptional Clinical Response to MEK Inhibition in a Patient With NRAS Mutation Positive NSCLC

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1428
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MEK-Inhibition Beim Inoperablen NRAS-mutierten Melanom

hautnah dermatologie
2017English

Quick and Sustained Clinical Response to MEK Inhibitor I in a NF1 Patient With Neurofibromas

ecancermedicalscience
Cancer ResearchOncology
2018English

An Acquired NRAS Mutation Contributes to Neutrophilic Progression in a Patient With Primary Myelofibrosis

British Journal of Haematology
Hematology
2017English

Report of the First Clinical Case of a Moroccan Kabuki Patient With a Novel MLL2 Mutation

Molecular Syndromology
Genetics
2013English

Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2015English

An Exceptional Case Report of Disseminated Cryptococcosis in a Hitherto Immunocompetent Patient

Revista do Instituto de Medicina Tropical de Sao Paulo
MedicineInfectious Diseases
2020English

P2.13-31 P.(Leu747Pro) Mutation Leads to Misdiagnosis in EGFR Mutation Assessment – Analysis in a Cohort of 1841 Polish NSCLC Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.cr-19 Thromboembolic Events Related to Immunotherapy in a NSCLC Patient: A Case Report.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy